EntryPoint Capital LLC Invests $276,000 in IQVIA Holdings Inc. (NYSE:IQV)

EntryPoint Capital LLC purchased a new stake in IQVIA Holdings Inc. (NYSE:IQV) in the fourth quarter, HoldingsChannel.com reports. The fund purchased 1,403 shares of the medical research company’s stock, valued at approximately $276,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Vanguard Group Inc. raised its holdings in shares of IQVIA by 0.5% during the 4th quarter. Vanguard Group Inc. now owns 20,131,734 shares of the medical research company’s stock worth $3,956,087,000 after buying an additional 105,504 shares in the last quarter. FMR LLC lifted its holdings in shares of IQVIA by 38.7% in the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after acquiring an additional 804,963 shares during the last quarter. Cantillon Capital Management LLC boosted its stake in shares of IQVIA by 12.3% in the 4th quarter. Cantillon Capital Management LLC now owns 2,066,144 shares of the medical research company’s stock valued at $406,018,000 after purchasing an additional 226,017 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of IQVIA by 46.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock valued at $437,378,000 after purchasing an additional 583,396 shares during the last quarter. Finally, Nordea Investment Management AB increased its position in IQVIA by 47.4% during the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after purchasing an additional 452,029 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Price Performance

IQV stock opened at $177.27 on Friday. IQVIA Holdings Inc. has a 1 year low of $176.03 and a 1 year high of $253.84. The stock has a market capitalization of $31.25 billion, a PE ratio of 23.64, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50. The company’s 50-day moving average is $193.15 and its 200-day moving average is $206.47. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Equities research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

IQV has been the topic of a number of research reports. StockNews.com cut shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Wednesday, March 12th. Citigroup lowered their target price on IQVIA from $225.00 to $210.00 and set a “neutral” rating for the company in a report on Tuesday, March 4th. Stephens began coverage on IQVIA in a research note on Friday, December 20th. They set an “overweight” rating and a $250.00 price target on the stock. JPMorgan Chase & Co. lowered their price objective on IQVIA from $240.00 to $232.00 and set an “overweight” rating for the company in a research note on Tuesday, February 18th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $270.00 target price on shares of IQVIA in a research report on Monday, February 10th. Five research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, IQVIA currently has a consensus rating of “Moderate Buy” and an average price target of $249.05.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.